Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review

Title:Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review

Volume: 17 Issue: 13

Author(s): Yuanchao Xie, Comfort Alicha Ogah, Xiangrui Jiang, Jianfeng Li and Jingshan Shen

Affiliation:

Keywords: Hepatitis C virus, inhibitor, nucleoside, NS5B polymerase, prodrug, SAR.

Abstract: Nowadays, a large number of people in the world are suffering from chronic Hepatitis C. HCV NS5B polymerase conserved across the identified 7 HCV genotypes is considered to be the most promising target in combating HCV. During the past decade, significant progress has been made in the discovery of novel nucleoside HCV NS5B polymerase inhibitors. A potent anti-HCV drug, sofosbuvir with high cure rates has been approved. Besides, quite a few nucleoside anti-HCV agents are being evaluated in clinical trials. The purpose of this review is to present recent progress in the development of nucleoside HCV NS5B polymerase inhibitors, focusing on lead compounds that hold great promise for medicinal use and their structure-activity relationships (SARs) in order to provide guidance for future drug design and discovery.

Cite this article as:

Xie Yuanchao, Ogah Alicha Comfort, Jiang Xiangrui, Li Jianfeng and Shen Jingshan, Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review, Current Drug Targets 2016; 17 (13) . https://dx.doi.org/10.2174/1389450117666151209123751